Gastrointestinal Cancers
Read Time: 6 mins

Using Epirubicin-loaded DC Beads® for Superselective Embolisation of Liver Tumours – Initial Experiences

Copy Link
Published Online: Jun 3rd 2011 European Oncology, 2008;4(1):72-6 DOI:
Authors: Wiskirchen Jakub, L Pereira Philippe
Quick Links:
Article Information

Hepatocellular carcinoma (HCC) is one of the leading causes of death worldwide, with a peak incidence in Asian countries. Unfortunately, by the time of diagnosis the disease is often so far advanced that the only curative treatment so far – surgery – cannot be performed in the majority of patients. In the past, several treatment strategies were developed to improve the quality and duration of life of patients suffering from HCC. These strategies included radiofrequency (RFA) and ethanol (PAI) ablation,1 laser interstitial tumour therapy (LIT),2 percutaneous alcohol injection (PAI) and transarterial chemoembolisation (TACE).3–6 In contrast to ablative procedures such as RFA, PAI and LIT, TACE is mainly suitable for the treatment of primary liver tumours such as HCC, which are predominantly supplied by branches of the hepatic arteries. Thus, it is possible to achieve a high concentration of antiproliferative drugs within the tumour in contrast to conventional intravenous (IV) chemotherapy.7,8 Due to the dual blood supply of the liver, normal tissue is not altered too much by this therapeutic strategy. Numerous protocols have been published describing the pros and cons of different antiproliferative drugs (including cisplatin, doxurubicin, epirubicin and mitomycin C) either alone or in combination with lipiodol. Furthermore, the use of additional embolic agents such as polyvinyl alcohol (PVA) particles or Gelfoam has been advocated in order to induce local hypoxia.9,10 The major disadvantage of conventional TACE is that the intratumoral concentration of the drug vastly decreases by the time it is washed out.

Drug-eluting Beads

Recently, microspheres (DC Beads®, Biocompatibles, UK), a sulfonate modified, PVA-based embolisation agent that can be labelled in the angio suite on site by the interventional radiologist with antineoplastic drugs such as doxrubicin or irinotecan, came onto the market.11,12 Using those particles provides two major advantages over conventional TACE. The drug charged to the particles is released to the surrounding tissue continuously in the first 10–12 days. This results not only in a higher overall intratumoral drug dose, but also in a longer period of drug application so that tumour cells re-entering the cell cycle can be treated over a longer period of time. However, due to the sustained drug release, the plasma levels of the charged drug are supposed to be lower than in conventional TACE, resulting in fewer systemic side effects. Furthermore, as the particles are available in different sizes (100–300μ, 300–500μ, 500–700μ and 700–900μ), effective arterial embolisation that results in local hypoxia can be achieved.

Drug-eluting Beads – Clinical Reports

The first reports describing the effectiveness of doxorubicin-releasing beads in the treatment of HCC have already been published. Varela et al.13 observed one- and two-year survival rates of 92 and 89.5%, respectively, in a small group of 27 patients suffering from HCC. In a group of 71 patients, Malagari et al. achieved even better survival rates of around 97% after one year and 91% after two years of follow-up.14 This is surprising, especially when bearing in mind that 44 patients of Malagari’s patient group presented with a Child Pugh score B and 27 presented with a Child Pugh score A. Poon et al. demonstrated the effectiveness of arterial chemoembolisation of HCC using doxorubicin beads according to the modified Response Evaluation Criteria in Solid Tumors (RECIST). Of their patients, 70% experienced a partial or even complete response.15

Drug-eluting Beads Labelled with Epirubicin Instead of Doxorubicin

In our practice, we used epirubicin in combination with DC Beads instead of doxorubicin, which is technically no problem as both substances can be charged to DC beads. We also used epirubicin for historical reasons. We have been using epirubicin in combination with lipiodol in our standard TACE protocol, thus we decided that it would make sense to have a ‘historical’ control group when switching to a new therapeutic scheme.
Between July 2005 and December 2007 we treated a total of 66 patients with epirubicin-loaded drug-eluting beads. The majority of patients (83%) suffered from HCC (singular, multifocal or diffuse HCC), and the remaining from metastases (neuroendocrine tumour, cholangiocellular carcinoma, melanoma). Most of the patients received between one and three treatment cycles; however, some patients received more than three cycles. The standard dose given was 50mg epirubicin per 2ml vial of DC Beads. Sometimes, a double-dose strategy with up to 100mg of epirubicin was pursued, especially in patients suffering from secondary liver tumours or HCC with large feeding vessels that were easy to catheterise.
In contrast to other groups, who administered up to 150mg of doxorubicin per intervention, we did not charge the maximum dose possible to the beads (i.e. epirubicin 75mg per 2ml vial) because we were afraid of possible toxic local or systemic side effects. Furthermore, as mentioned above, we appreciated a standard-dose (i.e. epirubicin 50mg per embolisation) strategy. This strategy was based on one case we experienced when treating a patient with a large diffuse HCC predominantly affecting the right liver lobe (see ‘Illustrated Case Study One’). In this patient, we followed a double-dose strategy and embolised a tumour mass, replacing more than two-thirds of the right liver lobe. The embolisation was successful and the patient was discharged from hospital two days later. However, the patient returned within a fortnight with right upper quadrant pain, fever and elevated liver enzymes. He recovered after 14 days in hospital; however, from then on he was treated with the standard dose of 50mg.
The standard particle sizes we used were 100–300 and 300–500μ, as we believed that it would be useful to deliver as many of the beads to the tumour tissue as possible. This could have been hampered by using large beads that occluded the tumour vessels at a more proximal level. In all cases, a contrast-enhanced computed tomography (CT) or magnetic resonance (MR) scan was obtained prior to the intervention. In cases where a CT scan was obtained, the pelvic vessels were also examined, thus giving the interventional radiologist an idea as to which material (sheath, etc.) to use. After catheterising the coeliac trunc or the superior mesenteric artery (SMA) (in case of a hepatomesenteric artery) with the help of a guiding catheter, an overview was obtained. A microcatheter was then used for superselective embolisation in order to treat as much of the tumour as possible while sparing the ‘healthy’ parts of the liver (see ‘Illustrated Case Study Two’). One day after intervention, a contrast-enhanced CT was obtained in order to document the areas of the tumour that were embolised properly, as well as documenting possible side effects related to the intervention. Overall, the procedure was tolerated well by most of the patients, even though we gave neither antiemetics nor antibiotics in advance.
The six- and 12-month survival rates achieved for the patients suffering from HCC were 93 and 90%, respectively, which are in line with the results published by Varela et al. but below the survival rates achieved by Malagari et al. One reason for this might be that when we began using DC Beads we exclusively used the 300–500μ Beads, which probably resulted in lower intratumoral drug doses. Furthermore, we treated nearly every patient, which means that even patients with large tumours replacing more than 50% of the liver were treated, as well as patients with partial portal vein thrombosis, extrahepatic tumour manifestations and other life-limiting conditions. On the other hand, although the patient population was not well selected, we observed very few complications, and most of these were related to the intervention. We observed two cases of cholecystitis when using the small beads (100–300μ); in one patient a cholecystectomy had to be performed. Additionally, we documented a total of three abscesses (see ‘Illustrated Case Study Three’). In the case of the patient with the large, diffuse growing HCC mentioned above (see ‘Illustrated Case Study One’), we were lucky not to lose the patient after the first ‘double-dose’ intervention, as the laboratory findings temporarily suggested nearby liver failure.


Using epirubicin-loaded particles may be beneficial in the transarterial treatment of primary liver tumours compared with conventional TACE. In our mind, a superselective approach is mandatory in order to minimise the rate of possible complications.

Illustrated Cases
Case Study One

A 66-year-old male patient suffering from active hepatitis C presented with an ill-defined, multifocal HCC with tumour nodules mainly in the right lobe. CT scans (see Figures 1a and 1b) showed a mainly hypervascular, multinodular HCC with some necrosis (see Figure 1b). Intra-arterial angiography performed with a 4F C2 Cobra catheter placed in the main hepatic artery confirmed the diagnosis of a large multinodular lesion (see Figure 1c). By using a 2.7F microcatheter (Progreat®, Terumo, Japan) the feeding vessels of the tumour were catheterised (see Figure 1d) and the tumour was embolised with a total of 4ml DC Beads enriched with epirubicin 100mg. The control angiography confirmed the vascular denudation of the tumour nodules in the right hepatic lobe (see Figure 1e). The nodules in the left lobe were not treated at this session in order to avoid stressing liver function too much in one session. A control CT scan obtained one day after the embolisation confirmed the vascular denudation of the tumour (see Figure 1f). Air bubbles within the tumour are a regular finding following DC Bead embolisation; they are not indicative of an abscess.

Case Study Two

A 53-year-old male patient suffering from hepatitis-C-induced liver cirrhosis presented with a well circumscribed, hypervascular HCC nodule in the right liver lobe in liver MR (see Figure 2a). Intra-arterial angiography using a 4F C2 Cobra catheter (see Figure 2b) confirmed the presence of a hypervascular lesion in the right liver lobe. After applying 2ml DC Beads loaded with epirubincin 50mg to the tumour and the surrounding tissue using a 2.7F microcatheter system (Progreat, Terumo, Japan), the tumour did not opacify any more (see Figure 2c). A control CT scan obtained one day after TACE confirmed the embolisation of the tumour. As in Case One, air bubbles within the tumour are regular findings following embolisation with DC Beads at our institution because the particles are suspended for a second time prior to embolisation. They do not represent an infectious complication (see Figure 2d).

Case Study Three

A 58-year-old male patient presented suffering from a diffusely growing HCC predominantly in the right liver lobe (see Figure 3a). After three cycles of DC Bead embolisation (each with 2ml of 300–500μ DC Beads enriched with epirubicin 50mg), the patient developed a biliary abscess close to the gall bladder (see Figures 3b and 3c). The abscess was drained percutaneously, and the patient was fine. ■


  1. Livraghi T, Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma, J Hepatobiliary Pancreat Surg, 2003;10:67–76.
  2. Vogl TJ, Mack MG, Straub R, et al., Interventionelle MR-gesteuerte laserinduzierte Thermotherapie bei onkologischen Fragestellunge, Radiologe, 1999;39:764–71.
  3. Llovet JM, Real MI, Montaña X, et al., Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 2002;359:1734–9.
  4. Lo CM, Ngan H, TSO WK, et al., Randomised controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 2002;35:1164–71.
  5. Camma C, Schepis F, Orlando A, et al., Transarterial CHemoembolization for Unresectable Hepatocellular CArcinoma: Meta-Analysis of Randomized Controlled Trials, Radiology, 2002;224:47–54.
  6. Clark HP, Carson WF, Kavanagh PV, et al., Staging and Current Treatment of Hepatocellular Carcinoma, Radiographics, 2005;25:S3–23.
  7. Konno T, Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium, Cancer, 1990;66:1897–1903.
  8. Egawa H, Maki A, Mori K, et al., Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil, dissolved in lipiodol on experimental liver tumor in rats, J Surg Oncol, 1990;44:109–14.
  9. Nakamura H, Hashimoto T, Oi H, Sawada S, Transcatheter oily chemoembolization of hepatocellular carcinoma, Radiology, 1989;170:783–6.
  10. Sasaki Y, Imaoka S, Fujita M, et al., Regional Therapy in the Management of Intrahepatic Recurrence after Surgery for Hepatoma, Ann Surg, 1987;206:41–7.
  11. Lewis AL, Gonzalez MV, Lloyd AW, et al., DC bead: in vitro characterization of a drug-delivery decive for transarterial chemoembolization, J Vasc Interv Radiol, 2006;17:335–42.
  12. Fiorentini G, Aliberti C, Turrisi G, et al., Intra-arterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads : results of a phase II clinical study, In Vivo, 2007;21:1085–91.
  13. Varela M, Real MI, Burrel M, et al., Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 2007;46:474–81.
  14. Malagari K, Alexopoulou E, Chatzimichail K, et al., Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: mid-term results of doxorubicin-loaded DC bead, Abdom Imaging, 2007; Epub ahead of print.
  15. Poon RTP, Tso WK, Pang RWC, et al., A Phase I/II Trial of Chemoembolization for Hepatocellular Carcinoma Using a Novel Intra-arterial Drug-Eluting Bead, Clin Gastroenterol Hepatol, 2007;5:1100–1108.

Further Resources

Share this Article
Related Content In Gastrointestinal Cancers
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72